Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
This doesn't look like a blinded trial, odds are, the primary researches were the ones performing the measurements. They were hoping for change and they found it.
The golf channel "big break" had it about right,,, pull the tape tight!, pull it tight!,,,, tight.
Either that or a slight slump to an upright position would do it.
Seems like common sense, if there is a muscle tone problem and no severe nerve problem,,, work the muscle and the tone improves but like other research there should be no spot reduction, the circumference finding would likely not be duplicated with an identical study.
but how many patients will put forth the time/effort of achieving that tone,, roughly the % of pts that lose the wt or become more active as asked to. Which is, not many.
patiently waiting and hopefully not for a write off.
Its been nice to gather information and read insights from this board, but also it would have been nice not to.
The science is very intriguing, as are many other things.
I think there is an extreme level of misconception when it comes to investing.
The first, relating to Cortex, is, placing your money in Cortex is speculation or day/short term trading and is in no way investing or an investment. Speculation/short term trading, period. In short term trading, there are charts and information to go on, but no solid base to those charts, just chart dynamics within a speculation company. There is absolutely no rationale way to call it investing.
There is always upside to speculation and therein lies the fun but the downside is always there and seems to come more often than the upside.
In every downside story, there will always be extremely smart people who believed in it and sometimes they were right but the opportunities were not there. There will always be extremely smart people who also do not believe in it.
I know exactly what brought me into speculation plays, mostly biotech and now will focus back on investing.
The downside is 0, forget value of the IP or anything else, the value to us shareholders is the value of the current share price and that includes the perceived potential.
No other value is there but the potential of value will be there until either the potential is verified somehow or the stock becomes completely worthless. The latter has the greatest likeliehood
I will hope that the potential is verified in the upcoming days/weeks but in all seriousness, if anyone is thinking about buying it in the near term as an investment, I'll do the longest nose grab I can.
The upside potential as others have talked about endlessly seems viable but it is potential that is comforting in nature regarding the significant past losses and giving hope to whatever remains. It's always nice to have hope. Shawshank redemption relayed it well regarding hope.
Until the last day there is upside, do you want to buy it the day before it croaks or do you want to wait until after something good happens. Which side would one rather second guess afterwards...
A couple other components to obese people are that,,,,,, they typically don't have the best posture, forward head, rounded shoulders, both of which makes it easy for them to have their arm fall asleep when they are on their side. With the nearly 50% reduction of space from the inferior portion of the coracoid to the superior humeral head that occurs in a protracted scapula/rounded shoulder vs a retracted scapula/good posture, the likelihood of having various stages of impingement and associated inflammation is very good in an obese population. I'd wager they will do what they can to sleep on their back vs. sleep on their side, tennis ball be darn.
What does others think about the 1 institutional investor regarding the financing.
Its not usually done through 1 entity??
My thoughts would be a little naive on it, hedge fund? Mutual fund? Bank?Possible interested pharma?
Its just a continuation of past events and at a much lower share price.
Cortex seems like such a promising company, its pipeline relatively different than others. There is plenty of more positive research on Ampas out there.
The problem is, what percentage of biotechs fail. Of those, probably some do have viable drugs.
Cortex has had an ever changing pipeline which low impact wise has appeared stronger the last year or two but which may also be stigmitized by the FDA and that may be on the mind of other companies.
high impacts, it doesn't matter at this point, there are new compounds but they carry the same weight as the older ones until they are put through a trial with good results, they are fodder until then.
It seems extremely poor sighted for the company to not have a deal by now, realists, the management is not (unless they have offers and are just relaying offer prices back and forth).
It seems extremely poor given the time from respiratory depression trial results to the current time with no concrete deal.
Is this a 5$+/Share company, based on the pipeline, it would seem so, but management can't expect to get a deal to their expectations and desires when they are still early in the trial phases.
If Cortex is holding out for SA results, if they are not positive, what of the deal process.
Of the current process, if other companies are far along and have tested the compounds, what does that mean if they aren't quick to put an offer up. Are there side effects that we haven't been privileged to know about. If you think otherwise, why do no one hear about the Phase 1,2 trials (especially the negative ones) and other from bigger pharmas
The PR may not be too bad, if actual progress in talks is being made and if positive SA results are identified.
From the past time of the 717debacle and the share price then to now, how on earth can you not strongly entertain the likelihood for the company to go under.
If they do, we the shareholders will get squat, it doesn't matter what anything they have may be worth, it won't equate to anything for us.
If you owned GM right now and you bought them 3 yrs ago for 50/sh, why wouldn't you believe the sky is falling.
Benedict only added shares to equal the required 30k; we can think of it as he thinks COR won't be going under but would anyone here know when his deadline for attaining 30k shares is? If he has a few more years to get them, then think it as a positive.
Don't forget, we don't know how long the "due diligence" period has been going on.
Anytime in Nov, Dec, Jan or early Feb.
They are not obligated to tell shareholders that a "due diligence phase" with one/more companies is being done.
Lets hope everything is in order and it gets completed soon.
With the current AMPA research discussed and the possibilities. If a company gives a small upfront and not much of a back-end loaded deal for RD but the upfront is enough to finish SA with good results, it would allow Cortex to shop around to their content for SA. It would not be in any companies interest to low ball Cortex in a RD deal where if good SA results come out, Cortex could take a different company up on an offer.
If the upfront is small enough to finish SA but the deal is loaded at the back, the share price will adjust accordingly and financing if needed will be done at better prices.
A big worry is, we haven't been privileged to see what the FDA letter in response to CX717 was and we haven't been privileged to read the toxicology tests done on the compounds. So we only know what we've been told and there can be a lot that we don't know.
From what has been released, I am extremely optimistic and things have been discussed repeated and rationally here many times but there is a little grey spot where we may not know things as clearly as we think we might.
As far as the OT topics regarding the economy, I am happy that there are so many good posters here and enjoy reading most, but I'd rather not read about the economy when looking to read about Cortex news. Today I think Bernanke stated he feels the markets and the recession may turn around before the end of this year.
When oil was 130, there was no end of people saying it will go to 150 and 200. There are people who say gold will go to 1500 and 2000. When the dow was rising, people were saying DOW 20K here we come, now people are saying DOW 5k. There is a guy on TV hocking natural cures for diabetes, arthritis and other diseases. All of these people are either fantastic orators or great at assimilating data to support their idea. Unless they are talking about biotech financing or Cortex or are trying to relate one to Cortex, I'd rather read about it on businessweek or watch it on TV.
Maybe there are different physiologic mechanisms associated with wakefulness, sleepiness, insomnia that we might not consider.
Why can some people drink coffee, soda or a couple of either and be able to sleep after.
What ways could a person be more alert, or be able to think clearer but also be able to go to sleep when they would like to.
Could an ampakine improve alertness or wakefulness but at the same time not affect that person of going to sleep or taking a nap if they were so inclined. I would think there are the connections and feedback loops and redundant networks to where this is very applicable at all dosages that have been utilized so far.
No need to stop there dear,
I think the next investments that us COR should go to should be a mix of GM, Citi, BofA and F to top it off.
I like the possibility of COR better, but your guess of GM is what the market thinks and the market thinks the same will happen to us and unfortunately there are a ton of biotechs, each with their own group of fans and shareholders who keep their own hopes high for the company. And most of those biotechs, the end value for shareholders is nil while GM shareholders will just be pinched for a long time
I am just hoping and believe from what information we have, our inklings are right and I feel Neuro and many of our good posters have had some rational thought behind there statements. Unfortunately some posters are flying more by emotion and without in a way that shows good reasoning.
Unfortunately, your suspicions are completely warranted when in relation to <5$/Sh biotechs or biotechs without multiple products in market.
Management and development minds of biotech seem to mostly have scientific minds which often do not have the best business insight and reasoning even if there are MBA credentials.
Negative history and stumbling blocks always will breed suspicion.
Probably management has been in discussion with various companies, but management cannot be stubborn with their inner valuation of the pipeline. Hopefully their data is good enough and their ability to sell the data is good enough to get a reasonable deal, back loaded or front loaded. If the data is not as good as we think, then management better modify their perception and take what they can get otherwise the current shareholder value is negligible.
If no discussions are getting close to reasonable, then I would expect a reverse split would have been appropriate in December or early January followed by a pipe.
I am still hoping that what has happened over the year, RD data and hopefully this year-good SA data, there will be very positive share price inducing news.
The past few years have seem to shown that financing would be done at a time which is prudent, unfortunately with the current financial climite, one could ponder that they have been trying to get a financing but have not been able to secure it.
As much as I'd like to think that a pipe or financing of some sort not being done by this point could be a positive, I don't think it is something to put much weight into.
As far as deals go, Cortex has gone to lengths to analyze the markets for RD and with RD alone should garner enough data for any interested companies for greater than 10 million front loaded into a deal.
I would wager that the analysis that developed 10million for upfronts took into account a very pessimistic scenario in addition to some deals that other companies attained.
Pain therapeutics regarding their signing with King Pharm, in addition to a great upfront of 150M also had King Pharm attain full cost responsibility for R+D.
This deal took place before any of the recent market crap started but maybe a deal with a well performing drug co could contain 15-50M upfront plus cost responsibility for R+D for RD.
Intriguing article. It has been an interesting year. Hopefully this year will progress significantly farther than last year regarding the potential of ampakines but with a progressive growth of good clinical data.
It seems like last year was the start of some research being finalized with more potent cortex ampakines not just initiated via cortex,, if the Cx 717 and more recent compounds have demonstrated adequate safety along with adequate efficacy and evolving efficacy in multiple indications, then the next 3 years may be very interesting,,,, as long as Cortex is able to maintain its business viability without delisting.
With the seemingly excellent growing amount of research on indications which the cortex amapkines are focused on in addition to the growing amount of research on cortex ampakines, horrible economy or not, it seems increasingly unlikely for a deal not to happen where cortex can gain cashflow to operate adequately.
Good luck but careful. Luckily I have only been invested in cortex for just over 3 years and unfortunately believe in the potential and the pharmacology behind ampakines and hope that Cortex has been and will be utilizing there cash flow appropriately and developing promising products to where they can actually come to market.
Careful with the alternative energy, that is another sector I have enjoyed researching but is in many ways seems more risk>reward than biotech.
GFP, neuro and others; I can understand the different possibilities that have been discussed for deals but could this process be significant impaired by our desire and corcentric view
Is it actually feasible to ink a deal where one compound can be given rights for one indication but rights for other areas of target indications for that same compound to be kept to Cortex.
I might assume a delay in finalizing a deal may come from the complexity of how many indications might one ampakine compound be viable for and for that, what %royality for all of those considerations would be appropriate.
Also, if low-impact compound x is ready for dealing but low-impacts 2x and 4x are around the corner and will have the same target indications but with likely better potency and maybe better results, then why would a company finalize a deal just for compound x when a competitor can finalize a deal for 2x or 4x and obtain the best in class or why would they finalize a deal for compound x and or 2x when that gives Cortex an ability to come out with compound 4x and end up with the best in class.
Maybe I am thinking this way because I am thinking that ampakines have a low-impact and a high-impact variability; but beyond those two categories how much variability is there. Not potency but variability. Is there variability with new low-impact compounds for the mech of action and pharmacodynamics to change.
Now maybe changing names from CX-xxx, xx1, to more independendly associated names for each compound would promote ease of splitting up different low impacts
What cortex probably needs is to find the best partner who would be able to increase the cortex royalities depending on the viability and progress of the low-impact compounds.
This would allow Cortex to partner the low-impacts and develop pet uses +high-impacts for sole Cortex use or until deemed fit to partner the high-impacts/other.
Then that means the worst is about over.
There will always be fearprophetering or something of the opposite.
Every time someone reads an article like that, no matter how well wrote, take it with one or many grains of salt.
Wasn't it not too long ago where prominent people were touting the continued climb of Google to 700+above or the price of oil to 200.
From this am. press release, "Cortex recently initiated additional human clinical trials for CX1739.....Assuming that the current Phase I studies are encouraging, Cortex plans to pursue CX1739 as a potential treatment for Attention Deficit Hyperactivity Disorder in Phase II efficacy trials during the second quarter of 200"
If a RD deal is made soon with liveable upfronts, then maybe good results of the recently initiated clinical trials for CX1739 may provide enough of a SP pop to help with financing at that time if needed.
That diabetic finding is interesting,,, proof for probably many theories; how many calories do we normally consume,, how many do we normally burn through activity. Not nearly enough prolonged or vigorous exercise to begin to utilize the amount or types of energy we consume.
For the recent posts, cortex seems to have a very positive looking pipeline,, but just for thoughts, does GFP or anyone have a little history of all known tested compounds?
The only compound of value so far is CX717, the newer compounds may be more potent, some of them may be safer but the early findings do not mean much at this stage and especially in this market. Though the last webcast Cortex had did show high probability for success with the new low impacts in RD, enough to be eternally optimistic and to throw Buffet/Grahams' philosophy of investment out the window.
One aspect people have not discussed is the veterinary pathway for Cortex; it would seem a quicker way to bring a product to market. Why hasn't SGP come into the recent possibilities? Not quite the pain company but it fits other indications for the ampakines.
I wouldn't mind a partnership with two companies, one pain-RD collaboration and one ADHD/AD collaboration.
We should be getting very close to results,, that is true and that is why the mental strain is starting to cause one of the first cases of human shedding, maybe an Ig nobel prize could be in order.
Results come out on one of the first 3days of next week, attached with small print at the end of the positive press-release. RD1 trial data was delayed due to a lost data CD from a head researcher while on vacation at a beach resort. Only evidence from the broken into vehicle was a banana peel left on the back seat. The trial was redone without cost to Cortex.
Prost! Oh, I miss those holidays and the beer. Nothing like a good Park or Bitburger.
It can also make for very interesting reads of the results afterwards.
But for this side, a country who could let pass the saying, Ich bein ein Berliner, is a country where things are relaxed and in no hurry.
If my memory serves me right, as long as early Alzh hasn't hit, didn't that translate as "I wish I was a donut hole"?
Myostrain
Slightly dubious. I am hoping for good news and from that good discussions regarding viable uses and good debate on future predictions. Too much chatter about nothing.
What happened with the RD#2 results before they were let out..? Didn't it seem like they either had the results for an unknown amount of time or knew exactly when they would receive those results....?
Lightheartedly, it sure would be nice if those European universities wouldn't spend labor day or MLK day on vacation despite the need of deadlines to be met.
If vacation from their side was the primary, what semester did the study start in?
Europeans, at least the Germans from my knowledge have a very nice number of work holidays but if vacations were the source of delay it would be more likely due to Cortex employee vacations. Even with that feeling, I am not against the strong possibility that key university personnel may typically go on a late summer holiday.
Now maybe the DSMB members if the same for both trials could have had a planned 2-3 week break b/w trials counting for the delay.
I only hope that the results come out before the preparation for Octoberfest..
That first paragraph is correct, there is really no need for big position holders or even small position holders to establish positions before the results are released.
Neuro's repeated comments on that there may be good time for buying if good results come in also are probably true.
Thankfully Cortex is a small company.
If any results come out positive, due to the company size, company history and people following the company, the initial pop may be very good but realization of good results may take some information processing after those results. That realization is why big position holders and others have no need for initial establishment.
As a message board, it seems the stockholders here have a sizeable sum, but what is the float, 46.8M shares, profit takers won't hold down the price much.
We have heard ad nauseum what good results may help facilitate, with good results any type of sp rise would still result in a very very good price range to buy in.
I just wish I could put more in my scottrade account to place an order if good results comes out, but hey, my current holdings would be enough for me to enjoy a new 6 pack of Shlitz and take enjoyment in the following years
OT- What are the signs a bubble is about to burst,, too much pumping and too many investment bundles. Different names but reminds me of the ways mortages were bundled, and those involved sound products-ever rising land and house values :)
What better way to have oil reach 200, 250 a barrel, but as well, what better way to have speculation or significant fuzzy math not just cause the increase but a decrease.
Good plays as long os you stay on your toes but..
Shame
That last statement Roger made is interesting. Hope to initiate tox testing of one of the two high impact analogs by year end.
Would that be considered the same as IND-enabling studies-late stage vs. an early stage study?
Would the lack of stating CX1837 be considered as a possible drop of that compound, it would seem illogical to state whats going on with CX1739 and CX1942 and not specifically state CX1837 on its progress.
Over the past few years, regarding the high impact compounds it almost seems warrented to give no weight of any high impact compounds until one actually starts a PH1.
Hoping I am not seeing a subtle drop of the high impact farthest along.
Good to know, cortex,,what is the meaning of a speculative biotech.
For companies like cortex I would lean towards being included in indexes such as the Russell Microcap is a significant deal.
For some reason I have tracked quite a few biotechs and fuelcell type companies, the small ones seem to move quite well with good news of joining similar type indexes. Different sector, but QTWW will be joining the Russell 3000Index; hopefully there won't be similar divergent paths this week.
At least a few of us can see this as another one of those buying opportunities ;)
Unfortunately there are no questions that anyone could ask Stoll where we could gleem anything that we don't already know.
One thing to remember, in big pharma trials the investors are typically kept outside the loop until results are out.
I would wager that an interim checklist/analysis is very common by DSMBs and the size of the trial makes it very susceptable to the need for more patients.
There is never a plan for a study to be halted due to safety findings, as there is never a plan prior to trial initiation to add more patients after interim analysis.
Just one of those things where every trial has data check points which if x happens then standard algorithms are initiated and appropriate actions are taken.
If a trial flows smoothly, that does not mean that check points, or DSMBs did not undergo intermittent analysis of the data. It is not prudent for Cortex or for the DSMB to give releases on each check point though it would be nice for anyone with ADHD or for those who have taken to enjoy the complex flavors of a nice rum or local beer over the last 2 years.
If adding subjects was to replace dropouts, what groups would be most likely to have dropouts. If there was great efficacy in only one group, would there be a need to replace dropouts? Is that different than great efficacy in multiple groups?
Does anyone have the slides of the study plan readily available?
For the number of patients in the study, what is the likely number of patients receiving placebo first and of those what may be a reasonable dropout rate of those,,, if a drop out rate of 25% for those receiving placebo was present then it would seem plausible for the need to add subjects.
Hopefully there was not a significant dropout from those receiving the drug, but due to the time of year and the patient types there probably is an inherently higher dropout rate.
If there was a placebo dropout rate of 25%, just 2 additional dropouts in any 2 of the dose groups may necessitate the need to add subjects
If the trial results are not optimal, possibly due to differences in the causes of RD, then there always is the pipeline and SGP which warrents more than 70cents
The Data Safety Monitoring Board (DSMB) saw no safety issues, but recommended including some additional patients in the study before proceeding to final analysis of the data.
I was hoping to hear news in the upcoming days but delays seem to involve every biotech.
My assumptions with this release are that the DSMB has no interest on whether the drug works at all, they are not considering if any particular dose is effective.
Ie. if the largest dosing demonstrated no effects, they would not recommend additional patients.
Due to the small sample size of the study, statistical analysis of safety as well as efficasy would be better with additional patients
There is a side thought that if the highest dosage demonstrated the most efficasy, because of the dosage amount, having more patients taking that amount analyzed would be prudent.
Until someone with expert knowledge of the responsibilites of te DSMB states other wise, we can surmise that the dosages did show some effect and possibily the higher dosages demonstrated more of an effect but in either case a larger sample size would benefit the analysis of safety data.
If the dosages showed now effect, then safety wise, why ask for more patients when there is no drug effect
It would always be a pleasant surprise for RD results to be let out ahead of schedule and be positive, along with a deal before or after RD results which solidifies the cashflow.
That being said, what would the royalty range be in?
If Greers company goes public, what is their pipeline and cash sources and expenses, and what is the growth potential of that company. I really doubt they would develop any significant products unless there were combination products involved and in that arena I would hope Cortex would have the main royalty.
I would lean towards the viability of Greer's company depends on their agreement with Cortex and as an investor in Cortex I hope the royality is minimal and view Greer's company as what neuro has stated and hopefully a company of small infrastructure.
If the deal with Greer's company has an above average royalty involved, and also if Cortex has deals with different BPs, the potential for Cortex's investors becomes squeezed more and more.
Good points of thought,
As a good investor, there should never be enough put into a stock like Cortex, especially at its stage in development to where a negative result would cause significant risk of financial stability to the investor; but then again there are always divergences with multiple facets.
Your statement that the rest of the world isn't watching Cortex with nearly the intensity we do, would serve you well.
The negative behind any trade possibility is zero.
What positives are known if good results are shown and what weak areas are solidified on good results have been off and on discussed
It is likely good results will have very good sp actions but no matter the possible positive action, the future growth would be significant with it.
If the decision for additional money into Cortex was being thought of, missing the initial uptick for future gains would seem most logical.
If good results are shown, I would not put much into the thought that quick financing would drive the sp down significantly.
If there are good results, Cortex will either make a quick deal with a company which will likely include a cash infusion or Cortex will make a financing which should be seen by the market as Cortex has data showing support and significant future income potential and are willing to grow the company and sp over any deal.
Although those thoughts of the market reactions may be too rational without regard to how things move in the market, the market may behave like a sleeping giant where the trial results may give it a nudge but the subsequent news may awaken it.
I am surprised there has not been any significant discussion on analgesia in the trials with respect to the analgesic receptor sites and MOA and review of ampakine receptor sites and pathways.
For a very simplified thought, what is the effect of taking a beta-blocker on pain relief from a cox-2 inhibitor. As far as opiates or barbiturates go, where do they exert their influence on reducing pain and in those areas are there any ampakine pathway connections which may negate their binding and action. Why would or how could an ampakine cause an effect at the opiate receptors with pain transmission or pain intensity or cause an effect with GABA receptors.
I think the implied experts were some of this board. Typical investors and investment funds will not take more than a blink of time at Cortex soley due to the share price and market cap.
R+Rs sp forecast for .30's, cash on hand, market cap, revenue, timeline proximity to revenue,, all adds to a very small group of people or companies with awareness of Cortex and some of those companies may not want to help spike the sp if they want to work on a deal.
One aspect of the RD-2 dosing that seems to be missed, half of the main objective.
Analyzing the safety of CX717
If they chose to go low, that could be interpreted that yes 900 and/or 1500 demonstrated efficacy but demonstrated side-effects so the lowest effective and safe dose would have to be found.
Chosing to go high, if a decision made based on 900+1500 data it would most likely have to be to see if CX 717 would also be safe at a much higher dosage. If it was done due to nonsignificant effect at 900 and 1500 then I will need to quench my thirst,, at least until something good finally, hopefully happens.
I would lean towards the side that the people who designed this trial have a "good" appreciation of CX717, its pharmacodynamics and kinetics, and target cells to be aware that if efficacy would be achieved, 900-1500 would be well within the expected effective range. That appreciation would include the full trials to date data including information that likely has not been published. No matter how intelligent outsiders looking in are, if outsiders don't have access to all pertinent data the assumptions made have greater chance for error.
There must be well thoughout analysis and awareness behind the decision for RD1 dosage to be what it is.
Scientists for the most part are scientists in and out, I'll leave it at that.
Probably a typo though patience may clear it up. In the pipeline status page, Org26576 is linked to depression only, while Org24448 was linked only to schizophrenia.
There is another strong negative towards financing before RD results.
Any agency involved will likely utilize the R+R data+forecasts.
Until tox results are in and are positive or RD results are in, the primary positive COR has in financing would be the SGP ampakine progress.
Cortex will do something to help there balance line, financing or a deal with another company. There seems to be no logic to do a financing before there are any positive tox or RD data. Prior to tox/RD data, financiers would use probability data that would lean towards the negative likeliehoods. Post tox/RD data financing, if tox or RD data were negative or inconclusive, the deal would likely have a nonsignificant difference in financing compared to a Pre tox/RD financing.
The only rational reasoning to do a financing pre RD results would be related to the timeline relating to the current cash burn rate and the timeline for performing a financing and receiving the financing. Prior discussion of the burn rate suggest there is enough time to wait until later in the year before taking the plunge.
OT-FYI, unfortunately if any spyware is unknowingly found its way on a computer, especially malware that is able to identify keystrokes+ on-line passwords, that computer would be at risk any time one logs onto a site/brokerage account. As long as a computer was infected, time of day wouldn't matter and number of applications open wouldn't matter.
That does bring a positive towards a second computer, one where you could use solely for important information/access, the other computer could be used for surfing/e-mail access.
great up to date virus/spyware software is always a necessity as well
This was an interesting read,
3. Investigation into the effects of chronic administration of the novel Ampakines Org 26576 and Org 24448 on functional activity, neurogenesis and receptor/signalling alterations in the murine cerebrum (Chronic administration of Org 26576 (1 mg/kg) and Org 24448 (10 mg/kg) induced functional cerebral increases in the mouse cerebrum particularly in areas of the mesocorticolimbic system, which were not only rapid in onset, with significant effects visible after 7 days administration; but importantly were also persistent and long lasting. These data show that the Ampakines Org 26576 and Org 24448 when administered chronically can potentiate complex neural networks intimately associated with disease states, the effects of which are maintained over prolonged periods.
Persisting and long lasting effects. 10:1 difference b/w 26576 and 24448.
Any thoughts on the possibility of use in patients with TIAs, strokes-recent vs chronic and symptom/location specificity?
what a redundant idea with no logical underpinnings,
the RD appears prior to the unexpected FDA ruling and can be attributed to general interest in ampakines and different minds desiring to test their hypotheses on how ampakines might work in different areas.
The use of earlier ampakines (pre-717)on those areas support this idea.
But I'm sure you're right, like Enron, American Home Mortage, New Century Financial; Cortex is in kahoots with the University of Alberta. The university of Alberta is a fictious university where Cortex was able to quickly fabricate some data with the "savior" indication once they "new" they needed to prevent a share price meltdown.
These things occur all the time at such perfect timing, why just this morning I was praying for guidance on my Cortex shares and before I had some oatmeal and coffee I could see the spitting image of the Virgin Mary in my oatmeal with a much smaller image of the head found on the cortex webpage, all of this before RD results come out, what perfect timing for me to buy more shares.
That article reminds me of recent stories of individual investors trying to take out their 401k assets after seeing a 10-15%drop; of a msn writer who wrote about how he invested relatively small amounts each year in bonds/CDs and his bank convinced him to invest some money in some market funds-a couple volitile ones for growth of which this writer became imbalanced to those funds which then did drop substantially after which he pulled all of his money from the funds.
Investing should be a long term strategy, trading is a short term high risk strategy. For traders, it might be good to rest on the sidelines but for investors it would be more prudent to stay with quality companies and continue layered investing.
No one can pick the bottom or the top, there may be significant downward flow left but maybe not as much as people think. Statistically, if you are down 19% at this point and you take out all of your stocks, and there is a 30%total correction, odds are you are not going to go back in at that bottom, and when you get in on the next upswing you will have missed a good percentage. On the other hand, if you are a prudent investor, not overweight in a high risk company and continue balanced investing on a monthly basis, in the long term your reward will be much greater.
Too much emotion in market articles without enough reasoning, read with caution.
Then you have to differentiate what is causing the adipose tissue in collapsing the airway. Or what is causing the mechanical apnea. It's probably not the adipose tissue, that would always be there, nice visual-beer gut swaying dependent on gravity. Where's the liposuction on that belly.
Now, if there is a tonal pathway abnormality causing hypotonia which then facilitates the mechanical obstruction when trying to sleep, the question could be; could ampakines facilitate the normalization of tone.
For thought, striated muscle tone is affected by afferents/efferents from the segmental level, various intra/extrafusal spindle fibers and other sensory organs, but there is also a vertical association UMN to LMN from more central regions on tone.
Could the central rhythm-generating networks, P.D. complex, ampakine affecting regions stimulate vertical pathway changes that facilitate peripheral pathway normalization and normalization of tone.
In these doldrums, at least the post FDA doldrums,
there are a lot of areas for concern and optimism
There is the known patent life for specific compounds discovered but two things for thought; is this the same type of patent life as what oxycodone, xyprexa has/had; secondly, don't drug companies find new ways to extend patents, vytorin.
Could Org-24448 finish phase 3 and go to market then a new study-RD/other cause an extension of the patent,, or maybe a combination pain reliever/org-24448 or other for a way to extend a patent.
Speaking of Org-24448 and Org-26576, why would they spend the money for continuing the trials if 1-they would not be able to bring them to market 2-if they thought ampakines did not show adequate risk reward for them
What does the continuation mean for Cortex- 1. money if brought to market 2. further collaboration for additional companies, merger, development agreement 3. ?Nixing the relevancy of near term solid financial ground. 4. Reducing the relevancy of RD results, extremely relevant, but the Org components are some nice extra logs in the fireplace.
One other thing on my mind, Cortex seems to do a great job on the studies which they design and complete, they have mostly done toxicology studies and animal studies. Maybe a review of all human studies they have done would be a good area to review.
Darpa would need to be considered as an outside study done by a non-biopharm company, and a political company none the less. Has anyone read results from a painreliever study in patients without pain or a BP med study in people without BP problems? Well, may we have read results of an alertness study for a possible alertness med when the study is done in a way to where actual alertness problems never truly were allowed to be present.
Statistics and data analysis on microbiotechs is not always that reliable in periods of meaningfull information. The current 60DMA, is the lull period after the drop in sp/high volume, where the volume was realisticly below average; The change from 45cents can be in association to shareholder buys, recent events from SP and associated progressive positive views on ampakines and maybe a little setting up or nibbling by daily Joe's and maybe the big-uns.
The volume was higher in the run up to 80cents, a good 300% off the 60DMA.
Stating "the mo mo boys are still not here" and "setting up" both seem to be relative valid statements
It would be interesting to do a review of the past 10trading days, volume, days range and ending range.
Today, over 500k traded which I believe is higher than yesterday and higher than most if not all of the previous 9 trading days.
Great down day for COR, nice initial rise and with how turbulent the US market/global market has been, a few people selling profit can be expected, I'd expect day traders who have tracked the recent chart data as well as some holders who have decided to take some profit. It looks like a decent uptick and volume towards the end of the day.
As far as the progressive volume of shares, I hope day traders would not be able create this progression and size we are seeing and am hoping that Cortex has been a busy little bee which in due time will have material data of a positive light to bear.